# Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from vaccinated individuals

Johannes Hayer[1]

Eva Urlaub[1]

[1]Roche Diagnostics GmbH, Mannheim, Germany

Corresponding author: Eva Urlaub, Roche Diagnostics GmbH, Mannheim, Germany, eva.urlaub@roche.com

**Running title**

SARS-CoV-2 rapid POC antibody test in a vaccinated cohort

**Abstract (242/250)**

*Objective*

The study aimed to establish the performance of the SARS-CoV-2 Rapid Antibody Test (IgG and IgM) and the Elecsys® Anti-SARS-CoV-2 S assay in vaccinated individuals.

*Methods*

A panel of serum samples from Boca Biolistics was utilized to assess antibodies following vaccination, consisting of samples drawn prior to vaccination, after the first dose, or at least 14 days after the second dose of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 COVID-19 vaccines. Agreement between the two methods was measured and stratified by test evaluator and assay lot.

*Results*

Agreement between the SARS-CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different assessment points for both mRNA-1273 and BNT162b2 ranged between 97.06% (95% confidence interval [CI] 84.67, 99.93) to 100% (95% CI 82.35, 100). Agreement of the SARS-CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay was not highly influenced by either lot or evaluator. There was a medium-to-strong correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) result and quantitative Elecsys Anti-SARS-CoV-2 S assay in samples taken after both doses of the vaccines, with higher intensity bands being associated with higher total anti-S antibody titer (mRNA-1273, $p=0.0019$; BNT162b2, $p<0.0001$).

*Conclusion*

Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S assay correlated well, suggesting that the SARS-CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response post-vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) in the vaccinated population.

**Importance (148/150)**

Serologic assays are an essential tool for quality control of vaccines and to determine the response to vaccination. Although a correlate of immunity has not yet been established for COVID-19 vaccines, antibody titers after natural infection and vaccination have been associated with protection from symptomatic SARS-CoV-2 infection. Rapid point-of-care assays can potentially be of use in this context with advantages over centralized testing, such as speed and ease of use. The point-of-care SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one or two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2. Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S assay results correlated well, suggesting that SARS-CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response post-vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) in the vaccinated population.

**Keywords**

antibodies, neutralizing; COVID-19 vaccines; immunity; immunoassay; nucleocapsid protein; point-of-care systems; SARS-CoV-2; spike protein

62 **Introduction**

63 Serologic immunoassays are vital in the global management of the COVID-19
64 pandemic. Measurement of antibodies to SARS-CoV-2 is important for improving
65 disease management, and accurate tests, with validated sensitivity and specificity,
66 are essential for obtaining reliable results when monitoring the pandemic (1).
67 Serologic assays can provide evidence of recent or past infection (2), and identify
68 those individuals still at risk of infection (3).

69 Infection with SARS-CoV-2 elicits a strong neutralizing antibody response (4), and
70 antibodies that bind via the spike protein act as neutralizing antibodies (5, 6). Several
71 studies have shown good correlation between anti-S antibodies and functional virus
72 neutralization (7-11). Neutralization assays utilizing live virus require biosafety level 3
73 containment, which can be labor intensive and low throughput (12-14); therefore
74 anti-S immunoassays, as a surrogate for neutralization, have an important role to
75 play (13, 15). On an individual patient level, anti-S immunoassays can confirm
76 vaccination status or inform upon the need for booster doses (16), which may be
77 helpful for both social and medical reasons.

78 Moderna mRNA-1273 (spikevax™) and Pfizer-BioNTech BNT162b2 (COMIRNATY®)
79 COVID-19 vaccines are mRNA vaccines, approved under the U.S. Food and Drug
80 Administration's emergency use authorization, each employing a two-dose regimen
81 (17, 18). The immune response involves B cells that produce binding and
82 neutralizing antibodies against the SARS-CoV-2 S protein (19, 20) and both
83 vaccines encode the SARS-CoV-2 spike protein to generate an immune response.
84 Serologic assays are an essential tool in vaccine quality control, being used to
85 determine the response to vaccination and providing insight into the antibody
86 response from the individual patient perspective (21, 22).

87 The Elecsys® Anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd,
88 Rotkreuz, Switzerland) is an electrochemiluminescence immunoassay (ECLIA),
89 which has been developed for quantitative *in vitro* detection of antibodies in human
90 serum and plasma (23). The assay detects total antibodies, including
91 immunoglobulin G (IgG), against the receptor binding domain (RBD) of the SARS-
92 CoV-2 spike protein, and is intended for use on the fully automated and high-
93 throughput cobas e analyzers (23). The assay has been shown to detect anti-S
94 antibodies across a variety of different populations (2, 24), and has been utilized as a
95 surrogate of neutralization activity (11, 25).

96 The SARS-CoV-2 Rapid Antibody Test (Roche Diagnostics International Ltd,
97 Rotkreuz, Switzerland) is CE-marked rapid chromatographic immunoassay intended
98 for the qualitative *in vitro* detection of both IgM and IgG antibodies to SARS-CoV-2
99 spike or nucleocapsid proteins in human serum, plasma or whole blood, for
100 professional use in the laboratory and at point-of-care (26). A study utilizing real-
101 world clinical samples in unvaccinated individuals demonstrated that the SARS-CoV-
102 2 Rapid Antibody Test had comparable performance with the Elecsys Anti-SARS-
103 CoV-2 assay that targets the nucleocapsid protein (27).

104 The objective of this study was to establish the performance of the SARS-CoV-2
105 Rapid Antibody Test and the Elecsys Anti-SARS-CoV-2 S assay in serum samples
106 obtained from individuals who had received a COVID-19 vaccination.

107 **Materials and Methods**

108 *Study design*

109 The study was a retrospective performance study conducted at Roche Diagnostics
110 GmbH (Mannheim, Germany). All samples were analyzed with the SARS-CoV-2

111 Rapid Antibody Test and compared with the Elecsys Anti-SARS-CoV-2 S assay.
112 Tests were conducted as per manufacturer's instructions (23).

113 *Samples*

114 To assess antibodies following vaccination, a post-vaccination panel was prepared
115 using 75 serum samples obtained from Boca Biolistics (Florida, USA), collected
116 between February and April 2021, and stored at -20°C or colder (all available
117 samples at the time of request). Serum samples were from individuals from the USA
118 sampled prior to vaccination, after the first dose, or at least 14 days after the second
119 dose of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (Supplemental Table
120 1).

121 Samples were separated into aliquots of 50 µL for the SARS-CoV-2 Rapid Antibody
122 Test measurement and 200 µL for the Elecsys Anti-SARS-CoV-2 S reference
123 measurement on the cobas® 6000 and stored at -80°C until use.

124 An in-house panel of 15 negative serum samples, previously determined negative by
125 Elecsys Anti-SARS-CoV-2 S assay, was utilized to assess the specificity of the
126 SARS-CoV-2 Rapid Antibody Test. Samples were collected in June 2021 as part of
127 an in-house blood donation service at Roche Diagnostics (Mannheim, Germany),
128 anonymized, and stored at -80°C until use. No information about vaccination status
129 was available. Evaluators were blinded as to the origin of the samples.

130 *SARS-CoV-2 Rapid Antibody Test*

131 The SARS-CoV-2 Rapid Antibody Test detects the presence of SARS-CoV-2 IgM
132 and IgG antibodies, and the intensity of the test line is dependent upon the level of
133 SARS-CoV-2 antibodies present in the sample (26). In unvaccinated individuals, the

134 reported sensitivity is 92.59% (7–14 days post-symptom onset [POS]) and 99.03%
135 (>14 days POS), with specificity of 98.65% (26).

136 Each sample was tested with two different lots of the SARS-CoV-2 Rapid Antibody
137 Test. The readout was visually assessed at 10 minutes by two different independent
138 evaluators; these evaluators were not the operators who had performed the test. In
139 accordance with manufacturer's instructions, the sample was considered positive if
140 the control line and at least one colored band/test line at G or M became apparent
141 (qualitative determination). As an exploratory analysis, results were further defined
142 by the intensity of the band to provide semi-quantitative data (Supplemental Table
143 2). Data are presented separated by lot and by evaluator. In the event of an invalid
144 result, the test would be repeated.

145 *Elecsys Anti-SARS-CoV-2 S assay*

146 The Elecsys Anti-SARS-CoV-2 S assay results are reported automatically as the
147 analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as
148 negative and ≥0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies
149 (23). The reported sensitivity and specificity of this test 14 days post-PCR is 97.92%
150 and 99.95%, respectively (24). The quantification range is between 0.4 and 250
151 U/mL and the reported limit of detection is 0.35 U/mL (23). If the sample
152 concentration is >250 U/mL, the sample can be diluted up to 1:100; in these cases,
153 the final result is determined as >25,000 U/mL (23).

154 In the event of an invalid result, the test would be repeated. All samples were
155 measured in duplicate, and the result calculated as the arithmetic mean of both
156 replicates. Assessors were blinded to the SARS-CoV-2 Rapid Antibody Test results
157 and blinded as to the origin of the samples.

158 *Statistical analysis*

159 The agreement rates comparing the SARS-CoV-2 Rapid Antibody Test with Elecsys
160 Anti-SARS-CoV-2 S assay per vaccine type were calculated per lot. Two-sided 95%
161 Clopper–Pearson confidence intervals (CI) for the agreement rates are given.
162 Correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test data
163 and quantitative Elecsys Anti-SARS-CoV-2 S assay data was assessed using the
164 Kendall's rank correlation $\tau$. Accuracy of the SARS-CoV-2 Rapid Antibody Test result
165 — how often do the qualitative results agree with one another — was assessed by
166 lot and evaluator. Statistical analyses were conducted using R (version 3.6.3) and
167 JMP (version 15).

168 **Results**

169 Overall, the study cohort consisted of 56 predominantly white/Caucasian individuals
170 (median age 70 years; 55.36% female) with a variety of pre-existing medical
171 conditions (Table 1). No invalid results were generated using either test.

172 *Analyses of the SARS-CoV-2 Rapid Antibody Test (qualitative) with the Elecsys Anti-*
173 *SARS-CoV-2 S assay (quantitative and qualitative)*

174 Eight samples were obtained from patients who were sampled prior to vaccination.
175 Whilst only two patients were reported to have been previously diagnosed with
176 COVID-19, only one patient was IgG and IgM negative (by both the SARS-CoV-2
177 Rapid Antibody Test and Elecsys Anti-SARS-CoV-2 S assay). For the seven positive
178 samples, Elecsys Anti-SARS-CoV-2 S total antibody titers ranged from 254.0 U/mL
179 to >25,000 U/mL and all were identified as positive by the SARS-CoV-2 Rapid
180 Antibody Test.

181 The post-vaccination antibody analysis included 25 samples from individuals
182 vaccinated with mRNA-1273 and 42 vaccinated with BNT162b2. The dosing interval
183 between first and second vaccine doses for BNT162b2 was a median of 21 days
184 (minimum 19 days, maximum 23 days) and a median of 28 days (minimum 21 days,
185 maximum 32 days) for mRNA-1273. There was good agreement between the SARS-
186 CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-SARS-CoV-2 S qualitative
187 measurements at the different assessment points for both the Moderna and Pfizer-
188 BioNTech vaccines ranging from 97.06% (95% CI 84.67, 99.93) to 100% (95% CI
189 89.72, 100) (Table 2). There was one false-negative sample with evaluator 2 (after
190 second dose of BNT162b2, lot 1 and lot 2), however this sample was classified as
191 positive by evaluator 1.

192 There was poor agreement between the SARS-CoV-2 Rapid Antibody Test (IgM)
193 and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different
194 assessment points for both BNT162b2 and mRNA-1273 ranging from 14.71% (95%
195 CI 4.95, 31.06) to 83.33% (95% CI 35.88, 99.58) with many false-negatives (Table
196 2).

197 Using the in-house negative panel, there were no false-positive results for either lot
198 or evaluator (Supplemental Table 3).

199 *Analyses of the SARS-CoV-2 Rapid Antibody Test (semi-quantitative) with the*
200 *Elecsys Anti-SARS-CoV-2 S assay (quantitative)*

201 There was a medium-to-strong correlation between the semi-quantitative SARS-
202 CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S
203 assay in samples taken after both doses of the vaccines (Figure 1), with higher
204 intensity bands being associated with higher total anti-S antibody titer (with Kendall's

205 τ up to 0.599 for IgG mRNA-1273 [p=0.0019] and 0.6833 [p<0.0001] for IgG
206 BNT162b2) (Supplemental Table 4). There was no correlation between the
207 quantitative Elecsys Anti-SARS-CoV-2 S assay result and the intensity of the SARS-
208 CoV-2 Rapid Antibody Test (IgM) (Supplemental Table 4).

209 Agreement between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgM)
210 and quantitative Elecsys Anti-SARS-CoV-2 S assay was poor, with many samples
211 designated as negative on the SARS-CoV-2 Rapid Antibody Test (IgM) even in the
212 presence of high anti-S antibody titers (Figure 2).

213 *Accuracy of the SARS-CoV-2 Rapid Antibody Test*

214 Comparison of the SARS-CoV-2 Rapid Antibody Test (IgG) results by lot or
215 evaluator revealed that these factors did not influence the results, with a minimum
216 accuracy estimate of 97.06% (Supplemental Figure 1).

217 SARS-CoV-2 Rapid Antibody Test (IgM) positivity appeared to be influenced by
218 evaluator, with a minimum accuracy estimate of 50% and considerable variability in
219 accuracy estimates across the different time points and vaccines (Supplemental
220 Figure 2).

221 *Evaluation of Elecsys Anti-SARS-CoV-2 S assay titer post-vaccination*

222 Antibody titers by days following final vaccination are shown in Figure 3. Following
223 complete vaccination with BNT162b2 or mRNA-1273 and up to approximately 20
224 days, there was significant variability with both high (maximum >25,000 U/mL) and
225 low (minimum 238.2 U/mL for BNT162b2 and 340.2 U/mL for mRNA-1273) anti-S
226 titers. After 30 days, anti-S titers for both vaccines commonly declined to below
227 5,000 U/mL (overall minimum 13.53 U/mL 25 days after vaccination with BNT162b2).

228 The median time between final vaccination and final measurement for those
229 vaccinated with BNT162b2 was 18 days (minimum 14 days, maximum 44 days) and
230 46 days (minimum 14 days, maximum 65 days) for mRNA-1273. Anti-S antibody
231 titers were numerically higher in participants vaccinated mRNA-1273 (median 2,307
232 U/mL; interquartile range [IQR] 872–6,845) than in those who received BNT162b2
233 (median 1,601 U/mL; IQR 467–3,131).

234 *Longitudinal analysis*

235 A small number of individuals had samples available from all three time points
236 (BNT162b2 cohort), allowing longitudinal evaluation of anti-S antibody titer levels; all
237 except one showed high levels of anti-S antibody titers at the first time point (prior to
238 vaccination). There was considerable variance in the effect of vaccination upon anti-
239 S antibody titers, however the greatest change was for the individual who was
240 infection-naïve (<0.4 U/mL to 1,645 U/mL following the second dose). For four
241 individuals, anti-S antibody titers actually decreased over time despite vaccination
242 with BNT162b2 (Supplemental Figure 3).

243 **Discussion**

244 Serologic assays are an essential tool for quality control of vaccines and to
245 determine the response to vaccination. Although a correlate of immunity has not yet
246 been established for COVID-19 vaccines, antibody titers after natural infection and
247 vaccination have been associated with protection from symptomatic SARS-CoV-2
248 infection (28); and rapid point-of-care assays can potentially be of use in this setting
249 with particular advantages over centralized testing, such as speed and ease of use.

250 We evaluated the use of the SARS-CoV-2 Rapid Antibody Test in vaccinated
251 individuals in comparison with the Elecsys Anti-SARS-CoV-2 S assay.

252 Our results indicate that the Elecsys Anti-SARS-CoV-2 S assay detects anti-S
253 antibodies after the first dose of both BNT162b2 and mRNA-1273, in agreement with
254 previous studies of the adaptive humoral response to vaccination in various
255 populations (21, 22, 29-33).

256 Whilst the performance of rapid antibody tests has been reported in unvaccinated
257 individuals (34-36), no studies have yet reported upon their use in vaccinated
258 individuals. The SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the
259 Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one
260 dose and two doses, similar to what has been observed in unvaccinated individuals
261 (27). Assessment of the influence of lot or evaluator revealed that agreement of the
262 SARS-CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay
263 was not highly influenced by either factor, suggesting that the SARS-CoV-2 Rapid
264 Antibody Test (IgG) is robust under normal usage conditions.

265 There was low agreement of the SARS-CoV-2 Rapid Antibody Test (IgM) with the
266 Elecsys Anti-SARS-CoV-2 S assay because, in general, there is a lower sensitivity
267 for IgM compared with IgG for point-of-care lateral flow assays, as exemplified in a
268 recent analysis of healthcare workers vaccinated with the first dose of the Pfizer
269 vaccine and sampled 21–24 days thereafter (37). In addition, the Elecsys Anti-
270 SARS-CoV-2 S assay preferentially detects high-affinity IgG antibodies that compete
271 with IgM antibodies (23), contributing to the lower agreement rates with IgM results.

272 The vaccines were administered in accordance with the relevant primary dosing
273 schedules, with approximately 3 weeks for BNT162b2 and 1 month for mRNA-1273
274 between doses (17, 18). Whilst the data reported herein suggest some variation in
275 the level of antibody titers afforded by the vaccines, two doses of either mRNA-1273

276 or BNT162b2 induced high levels of anti-S antibodies. Anti-S total antibody titers
277 were higher in participants vaccinated with mRNA-1273 than BNT162b2, in
278 accordance with previous publications (38). Whilst the clinical significance of
279 quantitative differences in antibody titers following COVID-19 vaccination have not
280 yet been established, understanding the differences in antibody titer can support
281 individual choices and assist with policy decisions.

282 Seven individuals in the BNT162b2 cohort appeared to have previously undiagnosed
283 SARS-CoV-2 infection prior to vaccination and the effect of vaccination upon anti-S
284 antibody titers in this group at the individual level was highly variable (relative
285 decrease or increase). Overall, after primary vaccination with two doses, all except
286 one of those with previous natural infection had higher anti-S antibody titers than the
287 infection-naïve participant, in agreement with previous reports which support higher
288 titers following vaccination in previously infected individuals (38-40).

289 The findings of this study are subject to several limitations. The performance of the
290 SARS-CoV-2 Rapid Antibody Test in vaccinated individuals was based on the
291 evaluation of a relatively small panel of samples and utilized only two vaccines.
292 However, the cohort tested was generally representative of an aged US population,
293 with hypertension and diabetes mellitus in line with age-related expectations of
294 prevalence (41, 42).

295 The clinical relevance of semi-quantitative results is currently unknown and, at
296 present, cannot be interpreted as an indication of varying levels of immunity.
297 However, semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative
298 Elecsys Anti-SARS-CoV-2 S assay results correlated well, suggesting that SARS-
299 CoV-2 Rapid Antibody Test (IgG) is helpful in understanding the immune response

post-vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) into the vaccinated population.

## Conflicts of interest

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: that JH and EU are employees of Roche Diagnostics; EU participates in Roche Connect; no other relationships or activities that could appear to have influenced the submitted work.

## Ethical approval and consent

Anonymized samples were provided by the commercial supplier Boca Biolistics and collected under their ethical approval system. Ethical approval for the in-house panel was provided by Ethik-Kommission II der Universität Heidelberg, Medizinische Fakultät, Mannheim, Germany. Samples were anonymized, and collected and tested in accordance with applicable regulations, including relevant European Union directives and regulations, and the principles of the Declaration of Helsinki.

## Data availability

Qualified researchers may request access to individual anonymized patient-level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here: https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm.

**Funding**

Roche Diagnostics GmbH (Mannheim, Germany) provided financial support for the study and for preparation of the article. Roche Diagnostics GmbH was involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Medical writing support was funded by Roche Diagnostics GmbH.

**Acknowledgements**

Medical writing support was provided by Corrinne Segal, Elements Communications Ltd, Westerham, UK. The authors would like to thank Rabea Held, Regina Draude, Maureen Adamietz, Shervan Horo, and Jlenia Marconi of Roche Diagnostics for their contribution to the study. COBAS, COBAS E, and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners'. The specific application (use in vaccinated individuals) is currently outside of the intended use of the SARS-CoV-2 Rapid Antibody Test. The Elecsys Anti-SARS-CoV-2 S assay is approved under an Emergency Use Authorization in the US.

340 **References**


341 1. Krammer F, Simon V. 2020. Serology assays to manage COVID-19. Science
342 368:1060–1061.

343 2. Riester E, Majchrzak M, Mühlbacher A, Tinguely C, Findeisen P, Hegel JK,
344 Laimighofer M, Rank CM, Schönfeld K, Langen F, Laengin T, Niederhauser C.
345 2021. Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2
346 immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect
347 Dis Ther doi:10.1007/s40121-021-00504-9:1–17.

348 3. Alter G, Seder R. 2020. The power of antibody-based surveillance. N Engl J Med
349 383:1782–1784.

350 4. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW,
351 Chan KH, Cheng SMS, Perera R, Cowling BJ, Poon LLM, Peiris M. 2021.
352 Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 12:63.

353 5. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S,
354 Vincent SP, Soumillion P, Alsteens D. 2020. Molecular interaction and inhibition
355 of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun 11:4541.

356 6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the
357 recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448.

358 7. Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C,
359 Paul A, Guibert N, D'Aubarède-Frieh C, Massardier-Pilonchery A, Fabien N,
360 Goncalves D, Boibieux A, Morfin-Sherpa F, Pitiot V, Gueyffier F, Lina B, Fassier
361 JB, Trouillet-Assant S. 2021. Evaluation of high-throughput SARS-CoV-2

362 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical
363 sensitivity, specificity, and association with virus neutralization test. Clin Chem
364 67:742–752.

365 8. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA,
366 Pallavicini L, Chinali A, Campisi D, Percivalle E, DiNapoli AP, Perno CF, Baldanti
367 F. 2020. Clinical and analytical performance of an automated serological test that
368 identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin
369 Microbiol 58:e01224–20.

370 9. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire
371 J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatziioannou
372 T, Jenks S, Bieniasz PD. 2021. Longitudinal serological analysis and neutralizing
373 antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis
374 223:389–398.

375 10. Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M,
376 Witt V, Schistal E, Schlenke P, Kreil TR, Jungbauer C. 2020. Quantification of
377 SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin
378 Virol 129:104540.

379 11. Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, Wölfel R, Girl P,
380 Müller K, Jochum S, Strobl M, Hoelscher M, Wieser A. 2021. In search of the
381 SARS-CoV-2 protection correlate: Head-to-head comparison of two quantitative
382 S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther
383 10:1505–1518.

384 12. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q,
385 Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and
386 validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg
387 Microbes Infect 9:680–686.

388 13. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS,
389 Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I,
390 Arinsburg S, Bandres JC, Siddiquey MNA, Schilke RM, Woolard MD, Zhang H,
391 Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Gamarnik AV, Hioe CE,
392 Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2021. Quantifying
393 absolute neutralization titers against SARS-CoV-2 by standardized virus
394 neutralization assay allows for cross-cohort comparisons of COVID-19 sera.
395 mBio 12:e02492–20.

396 14. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E,
397 Rouphael N, Edupuganti S, Shi PY, Menachery VD, Wrammert J, Suthar MS.
398 2020. Development of a rapid focus reduction neutralization test assay for
399 measuring SARS-CoV-2 neutralizing antibodies. Curr Protoc Immunol 131:e116.

400 15. Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B,
401 Pajon R. 2021. Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19
402 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial. medRxiv
403 doi:10.1101/2021.10.04.21264521:2021.10.04.21264521.

404 16. Baldanti F, Ganguly N, Wang G, Möckel M, O'Neill L, Renz H, Eduardo dos
405 Santos Ferreira C, Tateda K, Van Der Pol B. 2021. Deployment of SARS-CoV-2

406 diagnostic testing: challenges and key considerations for the future. Clin Rev Lab
407 Sci [submitted].

408 17. Pfizer-BioNTech. 2021. Fact sheet for healthcare providers administering
409 vaccine (vaccination providers): emergency use authorization (EUA) of the
410 Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019
411 (COVID-19). https://www.fda.gov/media/153713/download. Accessed 26 Nov
412 2021.

413 18. Moderna TX. 2021. Fact sheet for healthcare providers administering vaccine
414 (vaccination providers): emergency use authorization (EUA) of the moderna
415 COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19).
416 https://www.fda.gov/media/144637/download. Accessed 26 Nov 2021.

417 19. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M,
418 Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B,
419 Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B,
420 Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W,
421 Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH. 2021. Durability
422 of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 384:80–
423 82.

424 20. Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P,
425 Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle
426 JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. 2021. SARS-CoV-2 vaccination
427 in rituximab-treated patients: B cells promote humoral immune responses in the
428 presence of T-cell-mediated immunity. Ann Rheum Dis 80:1345–1350.

429 21. Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G,
430 Woclawek-Potocka I, Lukaszuk A, Rabalski L. 2021. Usefulness of IVD kits for
431 the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to
432 vaccination. Vaccines 9:840.

433 22. Salvagno GL, Henry BM, di Piazza G, Pighi L, De Nitto S, Bragantini D,
434 Gianfilippi GL, Lippi G. 2021. Anti-SARS-CoV-2 receptor-binding domain total
435 antibodies response in seropositive and seronegative healthcare workers
436 undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics 11:832.

437 23. Roche Diagnostics. 2021. Elecsys® Anti-SARS-CoV-2 S, instructions for use
438 (09289275190, V3.0, Dec 2021).

439 24. Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, Pessl F,
440 Laengin T, Niederhauser C. 2021. Performance evaluation of the Roche Elecsys
441 Anti-SARS-CoV-2 S immunoassay. J Virol Methods 297:114271.

442 25. Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. 2021. Performance
443 of the rapid high-throughput automated electrochemiluminescence immunoassay
444 targeting total antibodies to the SARS-CoV-2 spike protein receptor binding
445 domain in comparison to the neutralization assay. J Clin Virol 139:104820.

446 26. Roche Diagnostics/SD BioSensor. 2020. SARS-CoV-2 Rapid Antibody Test,
447 instructions for use (9901-NCOV-02C, V2.0, Sept 2020).

448 27. Findeisen P, Stiegler H, Lopez-Calle E, Schneider T, Urlaub E, Hayer J,
449 Zemmrich C. 2021. Clinical performance evaluation of a SARS-CoV-2 Rapid

450 Antibody Test for determining past exposure to SARS-CoV-2. Int J Infect Dis
451 103:636–641.

452 28. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao
453 K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are
454 highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
455 Nat Med 27:1205–1211.

456 29. Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice
457 R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb
458 CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum
459 S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T. 2021. Infliximab is
460 associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-
461 19 SARS-CoV-2 vaccines in patients with IBD. Gut 70:1884–1893.

462 30. Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, Maggiolo F.
463 2021. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in
464 subjects with previous SARS-CoV-2 infection. J Med Virol 93:4612–4615.

465 31. Cavalcanti E, Isgrò MA, Rea D, Di Capua L, Trillò G, Russo L, Botti G, Miscio L,
466 Buonaguro FM, Bianchi AAM. 2021. Vaccination strategy and anti - SARS-CoV-
467 2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer
468 Center (Naples, Italy). Infect Agent Cancer 16:32.

469 32. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T,
470 Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. 2021. Efficacy of the

471 BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic
472 leukemia. Blood 137:3165–3173.

473 33. Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, Ozcifci G,
474 Ozcaglayan A, Balkan, II, Saltoglu N, Tabak F, Hamuryudan V. 2021. Antibody
475 response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated
476 diseases: a controlled study among hospital workers and elderly. Rheumatol Int
477 41:1429–1440.

478 34. Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, Prostko J, Nebbia G,
479 Douthwaite S, Rodgers M, Cloherty G. 2020. A comparative evaluation between
480 the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™
481 SARS CoV-2 IgG assay. J Clin Virol 132:104645.

482 35. Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, Yang
483 D, Gelfand J, Bernstein BE, Feldman J, Hauser BM, Caradonna TM, Alter G,
484 Murali MR, Jasrasaria R, Quinlan J, Xerras DC, Betancourt JR, Louis DN,
485 Schmidt AG, Lennerz J, Poznansky MC, Iafrate AJ. 2020. High seroprevalence
486 of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis
487 222:1955–1959.

488 36. Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E,
489 Mai AL, Gilmour KC, Hatcher J, Scott C, Randell P, Mughal N, Jones R, Moore
490 LSP, Davies GW. 2020. Point-of-care serological assays for delayed SARS-CoV-
491 2 case identification among health-care workers in the UK: A prospective
492 multicentre cohort study. Lancet Respir Med 8:885–894.

493 37. Saluzzo F, Mantegani P, Poletti De Chaurand V, Quaresima V, Cugnata F, Di
494 Serio C, Macé A, De Vos M, Sacks JA, Cirillo DM. 2021. SARS-CoV-2 Antibody
495 Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiol
496 Spectr 9:e0025021.

497 38. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. 2021. Comparison of
498 SARS-CoV-2 antibody response following vaccination with BNT162b2 and
499 mRNA-1273. JAMA 326:1533–1535.

500 39. Di Meo A, Miller JJ, Fabros A, Brinc D, Hall V, Pinzon N, Ierullo M, Ku T, Ferreira
501 VH, Kumar D, Pasic MD, Kulasingam V. 2021. Evaluation of three anti-SARS-
502 CoV-2 serologic immunoassays for post-vaccine response. J Appl Lab Med Aug
503 3:jfab087.

504 40. Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S,
505 Apostolakou F, Sklirou AD, Gavriatopoulou M, Skourti S, Kastritis E, Korompoki
506 E, Papassotiriou I, Dimopoulos MA. 2021. Kinetics of anti-SARS-CoV-2 antibody
507 responses 3 months post complete vaccination with BNT162b2; A prospective
508 study in 283 health workers. Cells 10:1942.

509 41. Centers for Disease Control and Prevention. 2020. National diabetes statistic
510 report, 2020. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-
511 statistics-report.pdf. Accessed 24 Nov 2021.

512 42. Ostchega R, Fyar C, Nwanko T, Nguyen D. 2020. Hypertension prevalence
513 among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief
514 364:1–8.

515 **Tables and figures for ms**

516 Table 1: Demographics of the donors from the Boca Biolistics panel

517

| **Characteristics** | **All**<br><br>**N=56** | **Pfizer**<br><br>**n=34** | **Moderna**<br><br>**n=22** |
|---|---|---|---|
| **Male/female, %** | 44.64/55.36 | 44.12/55.88 | 45.45/54.55 |
| **Median age, IQR** | 70 (61.75–72) | 70 (63–71.75) | 71 (57.25–73) |
| **Ethnicity, %** | | | |
| Asian; Not Hispanic/Latino, | 1.79 | 2.94 | 0 |
| Black/African American; Not Hispanic/Latino | 3.57 | 5.88 | 0 |
| White/Caucasian; Not Hispanic/Latino | 64.29 | 61.76 | 68.18 |
| Hispanic/Latino; Black/African American | 7.14 | 8.82 | 4.55 |
| Hispanic/Latino; White/Caucasian | 23.21 | 20.59 | 27.27 |
| **Pre-existing medical conditions, %** | | | |
| Yes/No | 51.79/48.21 | 50.00/50.00 | 54.55/45.45 |
| Hypertension, Yes/No | 60.71/39.29 | 35.29/64.71 | 54.55/45.45 |

| | | | |
|---|---|---|---|
| Diabetes mellitus, Yes/No | 7.14/92.86 | 11.76/88.24 | 0/100 |

518 IQR, interquartile range

519 Table 2: Agreement between SARS-CoV-2 Rapid Antibody Test (IgG and IgM) and Elecsys Anti-SARS-CoV-2 S assay (reference
520 test) qualitative measurements as measured by lot and evaluator using the Boca Biolistics donor panel, and after one dose or at
521 least 14 days after two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2

522

| | | **mRNA-1273** | | | | | | | | **BNT162b2** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | **1 dose** | | | | **2 doses** | | | | **1 dose** | | | | **2 doses** | | | |
| | | **Evaluator 1** | | **Evaluator 2** | | **Evaluator 1** | | **Evaluator 2** | | **Evaluator 1** | | **Evaluator 2** | | **Evaluator 1** | | **Evaluator 2** | |
| | | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** | **Lot 1** | **Lot 2** |
| **Ig G** | **N** | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 8 | 8 | 8 | 8 | 34 | 34 | 34 | 34 |
| | **N +** | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 7 | 7 | 7 | 7 | 34 | 34 | 34 | 34 |
| | **N -** | - | - | - | - | - | - | - | - | 1* | 1* | 1* | 1* | - | - | - | - |
| | **TP** | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 7 | 7 | 7 | 7 | 34 | 34 | 33 | 33 |
| | **FN** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| | ***PPA, %*** | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *97.06* | *97.06* |
| | ***lower CI*** | *54.07* | *54.07* | *54.07* | *54.07* | *82.35* | *82.35* | *82.35* | *82.35* | *59.04* | *59.04* | *59.04* | *59.04* | *89.72* | *89.72* | *84.67* | *84.67* |

| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | ***upper CI*** | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *100* | *99.93* | *99.93* |
| **IgM** | **N** | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 8 | 8 | 8 | 8 | 34 | 34 | 34 | 34 |
| | **N +** | 6 | 6 | 6 | 6 | 19 | 19 | 19 | 19 | 7 | 7 | 7 | 7 | 34 | 34 | 34 | 34 |
| | **N -** | - | - | - | - | - | - | - | - | 1* | 1* | 1* | 1* | - | - | - | - |
| | **TP** | 2 | 2 | 5 | 4 | 4 | 4 | 6 | 4 | 2 | 2 | 3 | 2 | 6 | 6 | 5 | 5 |
| | **FN** | 4 | 4 | 1 | 2 | 15 | 15 | 13 | 15 | 5 | 5 | 4 | 5 | 28 | 28 | 29 | 29 |
| | ***PPA, %*** | *33.33* | *33.33* | *83.33* | *66.67* | *21.05* | *21.05* | *31.58* | *21.05* | *28.57* | *28.57* | *42.86* | *28.57* | *17.65* | *17.65* | *14.71* | *14.71* |
| | ***lower CI*** | *4.33* | *4.33* | *35.88* | *22.28* | *6.05* | *6.05* | *12.58* | *6.05* | *3.67* | *3.67* | *9.9* | *3.67* | *6.76* | *6.76* | *4.95* | *4.95* |
| | ***upper CI*** | *77.72* | *77.72* | *99.58* | *95.67* | *45.57* | *45.57* | *56.55* | *45.57* | *70.96* | *70.96* | *81.59* | *70.96* | *34.53* | *34.53* | *31.06* | *31.06* |

*1 sample was detected as antibody-negative by the Elecsys Anti-SARS-CoV-2 S and the SARS-CoV-2 Rapid Antibody Test.

+, positive by the reference test (Elecsys Anti-SARS-CoV-2 S assay); -, negative by the reference test (Elecsys Anti-SARS-CoV-2 S assay); CI, 95% confidence intervals; TP, true-positive; FN, false-negative; PPA, positive percent agreement

526 Figure 1: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgG vs Elecsys Anti-
527 SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-
528 1273 or Pfizer-BioNTech BNT162b2 (at least 14 days following second dose)




529

530 Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or
531 one of the five levels of increasing positivity based upon line intensity (((+)), (+), +,
532 ++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was
533 >25,000 U/mL. Blue = Lot 1; red = Lot 2; ○ = Evaluator 1; + = Evaluator 2.

534

535 Figure 2: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgM vs Elecsys Anti-

536 SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-

537 1273 or Pfizer-BioNTech BNT162b2 (at least 14 days following second dose)




538

539 Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or

540 one of the five levels of increasing positivity based upon line intensity (((+)), (+), +,

541 ++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was

542 >25,000 U/mL. Blue = Lot 1; red = Lot 2; ○ = Evaluator 1; + = Evaluator 2.

543

544 Figure 3: Elecsys Anti-SARS-CoV-2 S assay total antibody titer over time following

545 vaccination with Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (second dose)




546

547 Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was >25,000

548 U/mL. Blue = mRNA-1273; red = BNT162b2